How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

113,131 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients (...) Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2018 Clinical Trials

122. Faecal transplant effectively treats recurrent or unresponsive Clostridium difficile

studies. Faecal transplant techniques varied: lower or upper bowel application, fresh or frozen stools, and one or more infusion. Donors were family members and healthy volunteers, screened for viruses and gut problems. Follow up ranged from 10 weeks to eight years. Many studies used reduction in diarrhoea as a marker of effectiveness, rather than C. difficile toxin levels. The randomised trials were assessed as low risk of bias. Including case series, the range of interventions used and variation (...) included seven randomised controlled trials of 428 participants and 30 case series of 1,545 participants. Most studies looked at older adults; some included children and younger people with weakened immune systems. There were no UK based studies. Faecal transplant techniques varied: lower or upper bowel application, fresh or frozen stools, and one or more infusion. Donors were family members and healthy volunteers, screened for viruses and gut problems. Follow up ranged from 10 weeks to eight years

2018 NIHR Dissemination Centre

123. Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia

care (de Vugt et al. 2005; Miller et al. 2012). Other interventions can help in improving the culture and safety of the care environment and in conveying to patients and families that their needs and comfort are important. For most behavioral interventions there have not been a sufficient number of large-scale, well-controlled studies from which to draw conclusions about ef- ficacy or safety in treating agitation or psychosis (Brasure et al. 2016). When studies with less rigor- ous designs (...) the importance of involving patients and surrogate decision mak- ers, with input from family members and others. Perspectives of patients and their care partners highlight the need for such discussions and input at all steps of the decision-making and treatment- monitoring process to identify person-centered goals, values, and preferences that can shape care and enhance outcomes. In statements 4 and 6, which address treatment planning and review of response to nonpharma- cological interventions

2016 American Psychiatric Association

124. Functional Family Therapy (FFT) for Young People in Treatment for Non-Opioid Drug Use: A Systematic Review

aged 11-21 years enrolled for non-opioid drug use; 5 The Campbell Collaboration | www.campbellcollaboration.org ? used experimental, quasi-experimental or non-randomized controlled designs; ? reported at least one eligible outcome variable measuring abstinence, reduction of drug use, family functioning, education or vocational involvement, retention, risk behavior or other adverse effects; ? not focused exclusively on treating mental disorders; and ? had FFT as the primary intervention. DATA (...) to the problem behavior and to help family members develop specific skills in, for example, communication, conflict resolution, problem solving, and effective parenting. After the desired behavioral change has been achieved within the family, the therapist helps the family generalize changes to other situations and settings, such as school, community, and peers, and identifies support that can help to maintain the progress made (Sexton & Alexander, 2003; Onedera, 2006). As with many other forms of family

2015 Campbell Collaboration

125. Postpartum family planning

opportunities for PPFP 10 Evidence sources 11 Other publications reviewed 11 Appendix: Common and/or important side effects of contraceptive methods and which women should not use the method 12ii Best practice in postpartum family planning Best Practice Paper No. 1 Royal College of Obstetricians and Gynaecologists Introduction to the Best Practice Papers Professionals providing reproductive health care have a responsibility to ensure that the women and men they treat benefit from the latest evidence-based (...) may have about particular methods. Women should be invited to discuss their choice of contraceptive method with their partner or other family members if desired or appropriate. Women who have not decided on their chosen method should be given every opportunity to discuss contraception including during very early labour, if appropriate, or else immediately postpartum. If a woman brings her baby to a clinic for immunisation or if she attends a clinic for any other reason and she is not yet using

2015 Royal College of Obstetricians and Gynaecologists

126. Evaluation of a Novel Integrative and Intensive Virtual Rehabilitation Program for Service Members Post TBI

virtual reality (VR) therapeutic rehabilitative device (BrightBrainerTM) to treat patients with traumatic brain injury (TBI). These patients, service members with TBI, can be both with and without upper limb dysfunction and use uni- and bimanual virtual reality (VR) exercises to improve cognitive and motor function, as well as mood. Condition or disease Intervention/treatment Phase Traumatic Brain Injury Device: BrightBrainer Virtual Reality (BBVR) Rehabilitation System Not Applicable Detailed (...) -printed and a digital report. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 67 Years (Adult

2016 Clinical Trials

127. Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

and Afghanistan. Up to one-third of service members who sustain a TBI are diagnosed with a sleep disorder; insomnia being one of the most common. Currently, over half of TBI-associated insomnia cases remain untreated due to poor efficacy of available pharmacologic agents. Neuroendocrine dysfunction is an important mechanism linking TBI and disordered sleep, thus pharmacological agents that address this dysfunction may be effective in treating TBI-related insomnia. The neuroendocrine system is essential (...) [ Time Frame: 1-3 weeks ] Secondary Outcome Measures : Within and between group differences in plasma concentration levels of neuroendocrine proteins following tesamorelin administration compared to placebo [ Time Frame: 1-3 weeks ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you

2016 Clinical Trials

128. MDMA-assisted and Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads With One Member With Chronic PTSD

, a measure of PTSD symptoms Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older (...) MDMA-assisted and Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads With One Member With Chronic PTSD MDMA-assisted and Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads With One Member With Chronic PTSD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2016 Clinical Trials

129. Traditional medicine practices among community members with diabetes mellitus in Northern Tanzania: an ethnomedical survey. (PubMed)

Traditional medicine practices among community members with diabetes mellitus in Northern Tanzania: an ethnomedical survey. Diabetes is a growing burden in sub-Saharan Africa where traditional medicines (TMs) remain a primary form of healthcare in many settings. In Tanzania, TMs are frequently used to treat non-communicable diseases, yet little is known about TM practices for non-communicable diseases like diabetes.Between December 2013 and June 2014, we assessed TM practices, including types (...) to treat diabetes (40.3 %; 95 % CI 20.5-63.9), and individuals with diabetes reported seeking healthcare from traditional healers, elders, family, friends, and herbal vendors. We identified several plant-based TMs used toward diabetes care: Moringa oleifera, Cymbopogon citrullus, Hagenia abyssinica, Aloe vera, Clausena anisata, Cajanus cajan, Artimisia afra, and Persea americana.TMs were commonly used for diabetes care in northern Tanzania. Individuals with diabetes sought healthcare advice from many

Full Text available with Trip Pro

2016 BMC Complementary and Alternative Medicine

130. BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab

decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Be ≥ 18 years of age Have a life expectancy ≥ 6 weeks Have (...) BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2017 Clinical Trials

131. Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot

decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Squamous cell carcinoma T1 or T2 of the oropharynx or larynx (...) Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2017 Clinical Trials

132. Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.

peptide-1, pancreatic polypeptide, orexin A, alpha-melanocyte stimulating hormone...). Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information (...) Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants. Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2017 Clinical Trials

133. A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones

: TUS assessed on CT-scan [ Time Frame: 75-110 days after fracture occurrence ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages (...) A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2017 Clinical Trials

134. Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia

: Up to 12 Months ] Time to achieve sustained Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table (...) Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC) - Full Text View - ClinicalTrials.gov Hide glossary

2017 Clinical Trials

135. Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Age ≥ 18 Confirmation of GBM (WHO (...) Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

136. Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

estimates and 95% confidence intervals according to the methods in Duffy and Santner. Radiographic response rate will be compared between treatment arms using the 2-sample z-test to compare sample proportion at a one-sided 2.5% level of significance. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about (...) Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2017 Clinical Trials

137. Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer

assessed by The Self-Compassion Scale (SCS) Quality of Life [ Time Frame: Change from baseline until post treatment (10 weeks after baseline) and 6 months post treatment ] Change in Quality of Life assessed by the World Health Organization Well-being index (WHO-5) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn (...) Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2017 Clinical Trials

138. Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Main Study: Have active (...) Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

139. Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male or female patients with a diagnosis of CML-CP ≥ 18 years of age (...) Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

140. Strimvelis for treating adenosine deaminase deficiency?severe combined immunodeficiency

cell donor is available. Wh Why the committee made this recommendation y the committee made this recommendation ADA–SCID is a rare and serious condition that is fatal if untreated, and which severely affects the quality of life of people with the condition and their families. Treatment for ADA–SCID includes haematopoietic stem cell transplants (HSCTs). Clinical trial evidence shows that Strimvelis is effective in treating ADA–SCID. Compared with HSCTs, results suggest the main benefits (...) condition that also severely affects the lives of families and carers. Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 8 of 31Diagnosis and management Diagnosis and management 4.3 The committee heard from clinical experts that, when ADA–SCID is suspected, people will be referred to 1 of the 2 expert centres in England, where

2018 National Institute for Health and Clinical Excellence - Highly specialised technology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>